Effects of Dihydroergotamine and Etilefrine on Experimentally-Induced Postural Hypotension in Dogs
スポンサーリンク
概要
- 論文の詳細を見る
The effects of dihydroergotamine and etilefrine on experimentally-induced postural hypotension were examined. Although dihydroergotamine at 3 and 10 μg/kg (i.v.) increased blood pressure (BP), it did not affect cardiac output (CO). However, dihydroergotamine at 10μg/kg reduced the decrease in CO induced by the tilt. Therefore, it is suggested that the increase in BP is induced by the contraction of resistance vessels, and that the inhibition of the decrease in CO due to tilt is induced by the contraction of capacitance vessels. Etilefrine at 0.1 mg/kg (i.v.) increased BP and heart rate (HR), however it did not attenuate the decrease in BP induced by the tilt. Although it tended to increase CO, it did not attenuate the decrease in CO. It is suggested that the increase in BP is due to the contraction of resistance vessels, and to the increase in cardiac contractile force and HR. In this study, dihydroergotamine and etilefrine did not attenuate the decrease in BP due to tilt, though dihydroergotamine inhibited the decrease in CO due to tilt. As an explanation, it is suggested that dihydroergotamine induces contraction of resistance vessels as well as capacitance vessels, however the effects of the drug on resistance vessels is weak, and that etilefrine has little or no effect on capacitance vessels. In our previous study, midodrine, an alpha-1 agonist, attenuated the decreases in BP and CO due to tilt, and it has been suggested that the inhibition was induced by the contraction of capacitance vessels. Therefore, dihydroergotamine, etilefrine and midodrine show different pahrmacological profiles in experimentally-induced postural hypotension.
- 公益社団法人日本薬学会の論文
著者
-
YAMAZAKI Ryuzaburo
Research Center, Taisho Pharmaceutical Company, Ltd.
-
OTOMO SUSUMU
Research Center, Taisho Pharmaceutical Co., Ltd.
-
Otomo S
Research Center Taisho Pharmaceutical Co. Ltd.
-
TSUCHIDA Katsuharu
Research Center, Taisho Pharmaceutical Co., Ltd.
-
Yamazaki R
Research Center Taisho Pharmaceutical Co. Ltd.
-
Yamazaki Ryuzaburo
Research Center Taisho Pharmaceutical Company Ltd.
-
Tsuchida Katsuharu
Research Center Taisho Pharmaceutical Co. Ltd.
-
OTOMO Susumu
Research Center, Taisho Pharmaceutical Co., Ltd
関連論文
- Comparison of 26, 27-Hexafluoro-1α, 25-dihydroxyvitamin D_3 and 1α, 25-Dihydroxyvitamin D_3 on the Resorption of Bone Explants Ex Vivo
- INHIBITION OF PROSTAGLANDIN BIOSYNTHESIS BY A NEW ANTIINFLAMMATORY DRUG, TA-60
- ATTENUATION OF SEROTONIN-SUPPRESSED [^3H] ACETYLCHOLINE RELEASE FROM RAT HIPPOCAMPUS BY MINAPRINE : INVOLVEMENT OF 5-HT_2 RECEPTOR AND VOLTAGE-DEPENDENT K^+ CHANNEL
- Effects of Dihydroergotamine and Etilefrine on Experimentally-Induced Postural Hypotension in Dogs
- EFFECTS OF PROPRANOLOL ON TISSUE NECROSIS IN EXPERIMENTAL MYOCARDIAL INFARCTION IN DOGS
- EFFECTS OF PROPRANOLOL ON INFARCT SIZE AND THE IMPAIRED HEMODYNAMICS IN EXPERIMENTAL MYOCARDIAL INFARCTED DOGS
- CHARACTERISTICS OF GLUCOCORTICOID-BINDING SITES OF RAT LIVER: DIFFERENT EFFECTS OF ADRENALECTOMY ON THE BINDING
- Immunopharmacologic studies of D-penicillamine-L-cysteine disulfide.
- Cardiovascular effects of an ionophorous antibiotic, lonomycin A, in anesthetized dogs.
- Heterogeneity of binding sites for glucocorticoid and the glucocorticoid-receptor complex in rat livers.
- Characteristics of binding of a new anti-inflammatory glucocorticoid, hydrocortisone 17-butyrate 21-propionate (HBP), to glucocorticoid receptors of rat liver.